Efficacy and safety of dofetilide in the prevention of symptomatic episodes of paroxysmal supraventricular tachycardia: A 6-month double-blind comparison with propafenone and placebo
Background Existing drug therapies for paroxysmal supraventricular tachycardia (PSVT) have potentially serious adverse effects. Dofetilide, a pure class III antiarrhythmic agent, may offer an effective and safe alternative for treating PSVT. This study compared the efficacy and safety of dofetilide...
Gespeichert in:
| Veröffentlicht in: | The American heart journal 2001-07, Vol.142 (1), p.93-98 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 98 |
|---|---|
| container_issue | 1 |
| container_start_page | 93 |
| container_title | The American heart journal |
| container_volume | 142 |
| creator | Tendera, Michal Wnuk-Wojnar, Anna Maria Kulakowski, Piotr Malolepszy, Józef Kozlowski, J.W. Krzeminska-Pakula, M. Szechinski, Jacek Droszcz, Waclaw Kawecka-Jaszcz, Kalina Swiatecka, Grazyna Ruzyllo, Witold Graff, Ole |
| description | Background Existing drug therapies for paroxysmal supraventricular tachycardia (PSVT) have potentially serious adverse effects. Dofetilide, a pure class III antiarrhythmic agent, may offer an effective and safe alternative for treating PSVT. This study compared the efficacy and safety of dofetilide with that of propafenone and placebo in the prevention of PSVT. Methods This multicenter, randomized, placebo-controlled, parallel-group study compared the effectiveness of oral dofetilide 500 μg given twice daily with that of propafenone 150 mg given 3 times a day and placebo in preventing the recurrence of PSVT in 122 symptomatic patients. Episodes of PSVT were documented by symptom diaries and Hertcard (Hertford Medical, Hertfordshire, UK) event recorders. Results After 6 months of treatment, patients taking dofetilide, propafenone, and placebo had a 50%, 54%, and 6% probability, respectively, of remaining free of episodes of PSVT (P |
| doi_str_mv | 10.1067/mhj.2001.115439 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_70965808</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0002870301998370</els_id><sourcerecordid>70965808</sourcerecordid><originalsourceid>FETCH-LOGICAL-c304t-b7798def8f93074eb8fa0a83e463a48cce44d626f9e27197ba4b79eee2b68c5d3</originalsourceid><addsrcrecordid>eNp1kUFv1DAQhSMEokvhzA35gLhla8deO-FWVaUgVeICZ2tij7WuEjvYSSF_jN-H010JLpw89nzz_DSvqt4yumdUqqvx-LBvKGV7xg6Cd8-qHaOdqqUS4nm1o5Q2dasov6he5fxQrrJp5cvqgjHBmZR8V_2-dc4bMCuBYEkGh_NKoiM2lsoP3iLxgcxHJFPCRwyzj2Hr53Wc5jjC7A3ByedoMW_vE6T4a80jDCQvU4JtJHmzDJDIDOa4GkjWw0dyTWQ9xjAfy1dLP2DdD744MHEsEkUvkJ--NKcUp2IqxIBPDqcBDPbxdfXCwZDxzfm8rL5_uv1287m-_3r35eb6vjacirnulepai651HadKYN86oNByFJKDaI1BIaxspOuwUaxTPYhedYjY9LI1B8svqw8n3eLjx4J51qPPBocBAsYla0U7eWhpW8CrE2hSzDmh01PyI6RVM6q3qHSJSm9R6VNUZeLdWXrpR7R_-XM2BXh_BiAbGFyCYHz-R1eJA9-w7oRh2cOjx6Sz8RgMWp_QzNpG_18PfwBAb7TN</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>70965808</pqid></control><display><type>article</type><title>Efficacy and safety of dofetilide in the prevention of symptomatic episodes of paroxysmal supraventricular tachycardia: A 6-month double-blind comparison with propafenone and placebo</title><source>MEDLINE</source><source>ScienceDirect Journals (5 years ago - present)</source><creator>Tendera, Michal ; Wnuk-Wojnar, Anna Maria ; Kulakowski, Piotr ; Malolepszy, Józef ; Kozlowski, J.W. ; Krzeminska-Pakula, M. ; Szechinski, Jacek ; Droszcz, Waclaw ; Kawecka-Jaszcz, Kalina ; Swiatecka, Grazyna ; Ruzyllo, Witold ; Graff, Ole</creator><creatorcontrib>Tendera, Michal ; Wnuk-Wojnar, Anna Maria ; Kulakowski, Piotr ; Malolepszy, Józef ; Kozlowski, J.W. ; Krzeminska-Pakula, M. ; Szechinski, Jacek ; Droszcz, Waclaw ; Kawecka-Jaszcz, Kalina ; Swiatecka, Grazyna ; Ruzyllo, Witold ; Graff, Ole</creatorcontrib><description>Background Existing drug therapies for paroxysmal supraventricular tachycardia (PSVT) have potentially serious adverse effects. Dofetilide, a pure class III antiarrhythmic agent, may offer an effective and safe alternative for treating PSVT. This study compared the efficacy and safety of dofetilide with that of propafenone and placebo in the prevention of PSVT. Methods This multicenter, randomized, placebo-controlled, parallel-group study compared the effectiveness of oral dofetilide 500 μg given twice daily with that of propafenone 150 mg given 3 times a day and placebo in preventing the recurrence of PSVT in 122 symptomatic patients. Episodes of PSVT were documented by symptom diaries and Hertcard (Hertford Medical, Hertfordshire, UK) event recorders. Results After 6 months of treatment, patients taking dofetilide, propafenone, and placebo had a 50%, 54%, and 6% probability, respectively, of remaining free of episodes of PSVT (P <.001 for both dofetilide and propafenone vs placebo). Both dofetilide and propafenone also decreased the frequency of episodes of PSVT; the median numbers of episodes in the dofetilide- and propafenone-treated groups were 1 and 0.5, respectively, compared with 5 in the placebo-treated group. Dofetilide was well tolerated; no proarrhythmia occurred. Three patients taking propafenone had serious treatment-related adverse effects that required drug discontinuation. Conclusions Dofetilide and propafenone were equally effective in preventing the recurrence of or decreasing the frequency of PSVT. (Am Heart J 2001;142:93-8.)</description><identifier>ISSN: 0002-8703</identifier><identifier>EISSN: 1097-6744</identifier><identifier>DOI: 10.1067/mhj.2001.115439</identifier><identifier>PMID: 11431663</identifier><identifier>CODEN: AHJOA2</identifier><language>eng</language><publisher>New York, NY: Mosby, Inc</publisher><subject>Administration, Oral ; Aged ; Anti-Arrhythmia Agents - therapeutic use ; Antiarythmic agents ; Biological and medical sciences ; Cardiovascular system ; Double-Blind Method ; Female ; Humans ; Male ; Medical sciences ; Middle Aged ; Pharmacology. Drug treatments ; Phenethylamines - therapeutic use ; Propafenone - therapeutic use ; Proportional Hazards Models ; Sulfonamides - therapeutic use ; Survival Analysis ; Tachycardia, Supraventricular - prevention & control ; Treatment Outcome</subject><ispartof>The American heart journal, 2001-07, Vol.142 (1), p.93-98</ispartof><rights>2001 Mosby, Inc.</rights><rights>2001 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c304t-b7798def8f93074eb8fa0a83e463a48cce44d626f9e27197ba4b79eee2b68c5d3</citedby><cites>FETCH-LOGICAL-c304t-b7798def8f93074eb8fa0a83e463a48cce44d626f9e27197ba4b79eee2b68c5d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0002870301998370$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=1074533$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11431663$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Tendera, Michal</creatorcontrib><creatorcontrib>Wnuk-Wojnar, Anna Maria</creatorcontrib><creatorcontrib>Kulakowski, Piotr</creatorcontrib><creatorcontrib>Malolepszy, Józef</creatorcontrib><creatorcontrib>Kozlowski, J.W.</creatorcontrib><creatorcontrib>Krzeminska-Pakula, M.</creatorcontrib><creatorcontrib>Szechinski, Jacek</creatorcontrib><creatorcontrib>Droszcz, Waclaw</creatorcontrib><creatorcontrib>Kawecka-Jaszcz, Kalina</creatorcontrib><creatorcontrib>Swiatecka, Grazyna</creatorcontrib><creatorcontrib>Ruzyllo, Witold</creatorcontrib><creatorcontrib>Graff, Ole</creatorcontrib><title>Efficacy and safety of dofetilide in the prevention of symptomatic episodes of paroxysmal supraventricular tachycardia: A 6-month double-blind comparison with propafenone and placebo</title><title>The American heart journal</title><addtitle>Am Heart J</addtitle><description>Background Existing drug therapies for paroxysmal supraventricular tachycardia (PSVT) have potentially serious adverse effects. Dofetilide, a pure class III antiarrhythmic agent, may offer an effective and safe alternative for treating PSVT. This study compared the efficacy and safety of dofetilide with that of propafenone and placebo in the prevention of PSVT. Methods This multicenter, randomized, placebo-controlled, parallel-group study compared the effectiveness of oral dofetilide 500 μg given twice daily with that of propafenone 150 mg given 3 times a day and placebo in preventing the recurrence of PSVT in 122 symptomatic patients. Episodes of PSVT were documented by symptom diaries and Hertcard (Hertford Medical, Hertfordshire, UK) event recorders. Results After 6 months of treatment, patients taking dofetilide, propafenone, and placebo had a 50%, 54%, and 6% probability, respectively, of remaining free of episodes of PSVT (P <.001 for both dofetilide and propafenone vs placebo). Both dofetilide and propafenone also decreased the frequency of episodes of PSVT; the median numbers of episodes in the dofetilide- and propafenone-treated groups were 1 and 0.5, respectively, compared with 5 in the placebo-treated group. Dofetilide was well tolerated; no proarrhythmia occurred. Three patients taking propafenone had serious treatment-related adverse effects that required drug discontinuation. Conclusions Dofetilide and propafenone were equally effective in preventing the recurrence of or decreasing the frequency of PSVT. (Am Heart J 2001;142:93-8.)</description><subject>Administration, Oral</subject><subject>Aged</subject><subject>Anti-Arrhythmia Agents - therapeutic use</subject><subject>Antiarythmic agents</subject><subject>Biological and medical sciences</subject><subject>Cardiovascular system</subject><subject>Double-Blind Method</subject><subject>Female</subject><subject>Humans</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Pharmacology. Drug treatments</subject><subject>Phenethylamines - therapeutic use</subject><subject>Propafenone - therapeutic use</subject><subject>Proportional Hazards Models</subject><subject>Sulfonamides - therapeutic use</subject><subject>Survival Analysis</subject><subject>Tachycardia, Supraventricular - prevention & control</subject><subject>Treatment Outcome</subject><issn>0002-8703</issn><issn>1097-6744</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2001</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kUFv1DAQhSMEokvhzA35gLhla8deO-FWVaUgVeICZ2tij7WuEjvYSSF_jN-H010JLpw89nzz_DSvqt4yumdUqqvx-LBvKGV7xg6Cd8-qHaOdqqUS4nm1o5Q2dasov6he5fxQrrJp5cvqgjHBmZR8V_2-dc4bMCuBYEkGh_NKoiM2lsoP3iLxgcxHJFPCRwyzj2Hr53Wc5jjC7A3ByedoMW_vE6T4a80jDCQvU4JtJHmzDJDIDOa4GkjWw0dyTWQ9xjAfy1dLP2DdD744MHEsEkUvkJ--NKcUp2IqxIBPDqcBDPbxdfXCwZDxzfm8rL5_uv1287m-_3r35eb6vjacirnulepai651HadKYN86oNByFJKDaI1BIaxspOuwUaxTPYhedYjY9LI1B8svqw8n3eLjx4J51qPPBocBAsYla0U7eWhpW8CrE2hSzDmh01PyI6RVM6q3qHSJSm9R6VNUZeLdWXrpR7R_-XM2BXh_BiAbGFyCYHz-R1eJA9-w7oRh2cOjx6Sz8RgMWp_QzNpG_18PfwBAb7TN</recordid><startdate>20010701</startdate><enddate>20010701</enddate><creator>Tendera, Michal</creator><creator>Wnuk-Wojnar, Anna Maria</creator><creator>Kulakowski, Piotr</creator><creator>Malolepszy, Józef</creator><creator>Kozlowski, J.W.</creator><creator>Krzeminska-Pakula, M.</creator><creator>Szechinski, Jacek</creator><creator>Droszcz, Waclaw</creator><creator>Kawecka-Jaszcz, Kalina</creator><creator>Swiatecka, Grazyna</creator><creator>Ruzyllo, Witold</creator><creator>Graff, Ole</creator><general>Mosby, Inc</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20010701</creationdate><title>Efficacy and safety of dofetilide in the prevention of symptomatic episodes of paroxysmal supraventricular tachycardia: A 6-month double-blind comparison with propafenone and placebo</title><author>Tendera, Michal ; Wnuk-Wojnar, Anna Maria ; Kulakowski, Piotr ; Malolepszy, Józef ; Kozlowski, J.W. ; Krzeminska-Pakula, M. ; Szechinski, Jacek ; Droszcz, Waclaw ; Kawecka-Jaszcz, Kalina ; Swiatecka, Grazyna ; Ruzyllo, Witold ; Graff, Ole</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c304t-b7798def8f93074eb8fa0a83e463a48cce44d626f9e27197ba4b79eee2b68c5d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2001</creationdate><topic>Administration, Oral</topic><topic>Aged</topic><topic>Anti-Arrhythmia Agents - therapeutic use</topic><topic>Antiarythmic agents</topic><topic>Biological and medical sciences</topic><topic>Cardiovascular system</topic><topic>Double-Blind Method</topic><topic>Female</topic><topic>Humans</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Pharmacology. Drug treatments</topic><topic>Phenethylamines - therapeutic use</topic><topic>Propafenone - therapeutic use</topic><topic>Proportional Hazards Models</topic><topic>Sulfonamides - therapeutic use</topic><topic>Survival Analysis</topic><topic>Tachycardia, Supraventricular - prevention & control</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Tendera, Michal</creatorcontrib><creatorcontrib>Wnuk-Wojnar, Anna Maria</creatorcontrib><creatorcontrib>Kulakowski, Piotr</creatorcontrib><creatorcontrib>Malolepszy, Józef</creatorcontrib><creatorcontrib>Kozlowski, J.W.</creatorcontrib><creatorcontrib>Krzeminska-Pakula, M.</creatorcontrib><creatorcontrib>Szechinski, Jacek</creatorcontrib><creatorcontrib>Droszcz, Waclaw</creatorcontrib><creatorcontrib>Kawecka-Jaszcz, Kalina</creatorcontrib><creatorcontrib>Swiatecka, Grazyna</creatorcontrib><creatorcontrib>Ruzyllo, Witold</creatorcontrib><creatorcontrib>Graff, Ole</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>The American heart journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Tendera, Michal</au><au>Wnuk-Wojnar, Anna Maria</au><au>Kulakowski, Piotr</au><au>Malolepszy, Józef</au><au>Kozlowski, J.W.</au><au>Krzeminska-Pakula, M.</au><au>Szechinski, Jacek</au><au>Droszcz, Waclaw</au><au>Kawecka-Jaszcz, Kalina</au><au>Swiatecka, Grazyna</au><au>Ruzyllo, Witold</au><au>Graff, Ole</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Efficacy and safety of dofetilide in the prevention of symptomatic episodes of paroxysmal supraventricular tachycardia: A 6-month double-blind comparison with propafenone and placebo</atitle><jtitle>The American heart journal</jtitle><addtitle>Am Heart J</addtitle><date>2001-07-01</date><risdate>2001</risdate><volume>142</volume><issue>1</issue><spage>93</spage><epage>98</epage><pages>93-98</pages><issn>0002-8703</issn><eissn>1097-6744</eissn><coden>AHJOA2</coden><abstract>Background Existing drug therapies for paroxysmal supraventricular tachycardia (PSVT) have potentially serious adverse effects. Dofetilide, a pure class III antiarrhythmic agent, may offer an effective and safe alternative for treating PSVT. This study compared the efficacy and safety of dofetilide with that of propafenone and placebo in the prevention of PSVT. Methods This multicenter, randomized, placebo-controlled, parallel-group study compared the effectiveness of oral dofetilide 500 μg given twice daily with that of propafenone 150 mg given 3 times a day and placebo in preventing the recurrence of PSVT in 122 symptomatic patients. Episodes of PSVT were documented by symptom diaries and Hertcard (Hertford Medical, Hertfordshire, UK) event recorders. Results After 6 months of treatment, patients taking dofetilide, propafenone, and placebo had a 50%, 54%, and 6% probability, respectively, of remaining free of episodes of PSVT (P <.001 for both dofetilide and propafenone vs placebo). Both dofetilide and propafenone also decreased the frequency of episodes of PSVT; the median numbers of episodes in the dofetilide- and propafenone-treated groups were 1 and 0.5, respectively, compared with 5 in the placebo-treated group. Dofetilide was well tolerated; no proarrhythmia occurred. Three patients taking propafenone had serious treatment-related adverse effects that required drug discontinuation. Conclusions Dofetilide and propafenone were equally effective in preventing the recurrence of or decreasing the frequency of PSVT. (Am Heart J 2001;142:93-8.)</abstract><cop>New York, NY</cop><pub>Mosby, Inc</pub><pmid>11431663</pmid><doi>10.1067/mhj.2001.115439</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0002-8703 |
| ispartof | The American heart journal, 2001-07, Vol.142 (1), p.93-98 |
| issn | 0002-8703 1097-6744 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_70965808 |
| source | MEDLINE; ScienceDirect Journals (5 years ago - present) |
| subjects | Administration, Oral Aged Anti-Arrhythmia Agents - therapeutic use Antiarythmic agents Biological and medical sciences Cardiovascular system Double-Blind Method Female Humans Male Medical sciences Middle Aged Pharmacology. Drug treatments Phenethylamines - therapeutic use Propafenone - therapeutic use Proportional Hazards Models Sulfonamides - therapeutic use Survival Analysis Tachycardia, Supraventricular - prevention & control Treatment Outcome |
| title | Efficacy and safety of dofetilide in the prevention of symptomatic episodes of paroxysmal supraventricular tachycardia: A 6-month double-blind comparison with propafenone and placebo |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-12T14%3A53%3A59IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Efficacy%20and%20safety%20of%20dofetilide%20in%20the%20prevention%20of%20symptomatic%20episodes%20of%20paroxysmal%20supraventricular%20tachycardia:%20A%206-month%20double-blind%20comparison%20with%20propafenone%20and%20placebo&rft.jtitle=The%20American%20heart%20journal&rft.au=Tendera,%20Michal&rft.date=2001-07-01&rft.volume=142&rft.issue=1&rft.spage=93&rft.epage=98&rft.pages=93-98&rft.issn=0002-8703&rft.eissn=1097-6744&rft.coden=AHJOA2&rft_id=info:doi/10.1067/mhj.2001.115439&rft_dat=%3Cproquest_cross%3E70965808%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=70965808&rft_id=info:pmid/11431663&rft_els_id=S0002870301998370&rfr_iscdi=true |